Skip to main content
Premium Trial:

Request an Annual Quote

Noninvasive Endometriosis Test Developer DotLab Secures $10M in Series A Funding

NEW YORK – Women's health personalized medicine company DotLab said on Monday it has secured $10 million in Series A funding.

The San Francisco-based firm is combining noninvasive microRNA biomarkers with machine learning to develop a noninvasive test for endometriosis. In a statement, DotLab CEO Heather Bowerman said that the company will use the funds to "further clinical validation, expand market access, and continue to grow our team."

CooperSurgical, a business unit of The Cooper Companies, led the financing, which also included individual investors from Tiger Global Management, Luxor Capital Group, and the law firm Wilson Sonsini Goodrich & Rosati.

The DotLab test detects microRNA biomarkers, but it is not a genetic test for endometriosis, and the risk profiles do not confirm active disease, Bowerman said in an email.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more